Pancreatic Cancer Market Report

1. Pancreatic Cancer Market to Grow Positively at a Paltry CAGR During the Study Period (2019–2032), asserts DelveInsight | Major companies involved: AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol-Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, Bristol-Myers Squibb United States, Nevada, Las Vegas, DelveInsight’s ‘Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of pancreatic cancer historical and forecasted epidemiology as well as the pancreatic cancer market trends in the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The pancreatic cancer market report provides current treatment practices, emerging drugs, and market share of individual therapies, current and forecasted 7MM pancreatic cancer market size. The report also covers current pancreatic cancer treatment practice, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. Pancreatic Cancer Overview Pancreatic cancer initiates in the pancreatic tissues, situated in the abdomen behind the lower portion of the stomach. The pancreas plays a vital role in digestion by releasing enzymes and regulating blood sugar through hormone production. This disease involves the formation of malignant cells within the pancreas tissues, which can manifest as various types of growth, both cancerous and noncancerous. The most prevalent form arises from the cells lining the ducts responsible for transporting digestive enzymes (known as pancreatic ductal adenocarcinoma). Detecting pancreatic cancer early, when it's most treatable, is challenging as it typically presents no symptoms until it has already metastasized. Treatment options, such as surgery, chemotherapy, and radiation therapy, or a combination thereof, depend on the cancer's extent.

2. Pancreatic cancer develops when cells within the pancreas undergo mutations in their DNA, disrupting normal cellular functions. These mutations prompt uncontrolled cell growth and evasion of programmed cell death, resulting in tumor formation. Left untreated, pancreatic cancer cells can migrate to neighboring organs, blood vessels, and distant parts of the body. Pancreatic Cancer Epidemiological Insights ● In 2021, the total incident cases of pancreatic cancer in the 7MM countries were 175,767 cases, and these cases are anticipated to increase during the study period. ● Among the European countries, Germany had the highest incident cases of pancreatic cancer in 2021, i.e., 21,859 cases, followed by France which had 14,989 incident cases in 2021. On the other hand, Spain had the lowest incident cases of pancreatic cancer, i.e. 8,566 cases in 2021. Japan had 43,170 incident cases of pancreatic cancer in 2021. ● In terms of stage-specific incident cases, maximum number of patients were observed for distant pancreatic cancer. This was followed by regional and localized pancreatic cancer. ● According to DelveInsight, the majority of pancreatic cancer cases are caused by KRAS2 mutation followed by TP53 and SMAD4/DPC4 mutations. Least number of incident cases were observed for pancreatic cancer associated with NTRK mutation. ● As per DelveInsight analysis, the Pancreatic Cancer market is anticipated to witness growth at a considerable CAGR. ● The total Pancreatic Cancer market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major Pancreatic Cancer markets. Pancreatic Cancer Market Outlook Pancreatic cancer ranks among the most prevalent cancers globally and stands as the seventh leading cause of cancer-related deaths. Its occurrence is on the rise, particularly in Western countries. The incidence of pancreatic adenocarcinoma, a common type of pancreatic cancer, is increasing in developed regions, with lifestyle factors like alcohol consumption and obesity potentially contributing. Despite advancements in surgical procedures, chemotherapy protocols, and the

3. introduction of neoadjuvant chemoradiotherapy, the five-year survival rate remains alarmingly low, plummeting to as little as 2% in certain nations. Presently, chemotherapy forms the cornerstone of treatment for pancreatic cancer patients. Pancreatic ductal adenocarcinoma (PDAC) represents a significant portion of pancreatic cancer cases. Despite progress in surgical and chemotherapy techniques, survival rates remain dismal. Late-stage diagnosis, typically at Stage III or IV, greatly hampers treatment effectiveness, with many patients ineligible for intervention by this stage, often presenting with metastatic disease. Surgery is most effective in localized or regional cancer cases, which are infrequently encountered at diagnosis. Research by Kasumova et al. (2017) revealed that only approximately 35% of patients had Stage I/II diagnoses, with the majority diagnosed at Stage III/IV. Of those diagnosed at Stage I/II, a relatively low percentage underwent tumor resection. The study also noted an uptick in neoadjuvant therapy utilization among early-stage patients. In advanced stages, a significant portion of patients receive chemotherapy and/or radiation therapy, though proportions remain suboptimal, particularly among Stage III and IV cases. Promising Therapies in Pancreatic Cancer Pipeline ● Motixafortide (BL-8040) ● Anktiva (N-803) ● SBP-101 Discover more about Pancreatic Cancer therapies in the pipeline @ Pancreatic Cancer Leading Companies Working in Pancreatic Cancer Market ● AstraZeneca ● Merck Sharp & Dohme LLC ● Bayer ● Roche ● Celgene ● Bristol-Myers Squibb ● BioLineRx ● Alligator Bioscience

4. ● Bellicum Pharmaceuticals ● OSE Immunotherapeutics ● Actuate Therapeutics ● FibroGen ● NeoImmuneTech ● OXXON Pharma ● Silenseed Ltd. ● Amgen ● NGM Biopharmaceuticals ● Merus ● Mirati Therapeutics ● Rexahn Pharmaceuticals ● Ocuphire Pharma ● Processa Pharmaceuticals ● ImmunityBio ● Berg ● Panbela Therapeutics ● GlaxoSmithKline ● Eleison Pharmaceuticals ● Molecular Templates ● Lokon Pharma AB ● Cantargia AB ● Bristol-Myers Squibb Learn more about the recent developments and breakthroughs in the Pancreatic Cancer market @ Pancreatic Cancer Clinical Trials Scope of Pancreatic Cancer Market Report Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan] Key Pancreatic Cancer Companies: AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol-Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM

5. Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, Bristol-Myers Squibb Key Pancreatic Cancer Pipeline Therapies: Motixafortide (BL-8040), Anktiva (N-803), SBP-101, and others Therapeutic Assessment: Pancreatic Cancer current marketed and emerging therapies Pancreatic Cancer Market Dynamics: Pancreatic Cancer market drivers and barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies Unmet Needs, KOL’s views, Analyst’s views, Pancreatic Cancer Market Access and Reimbursement Table of Contents 1. Pancreatic Cancer Market Key Insights 2. Pancreatic Cancer Market Report Introduction 3. Pancreatic Cancer Market Overview at a Glance 4. Pancreatic Cancer Market Executive Summary 5. Disease Background and Overview 6. Pancreatic Cancer Treatment and Management 7. Pancreatic Cancer Epidemiology and Patient Population 8. Patient Journey 9. Pancreatic Cancer Emerging Drugs 10. 7MM Pancreatic Cancer Market Analysis 11. Pancreatic Cancer Market Outlook 12. Potential of Current and Emerging Therapies

6. 13. KOL Views 14. Pancreatic Cancer Market Drivers 15. Pancreatic Cancer Market Barriers 16. Unmet Needs 17. SWOT Analysis 18. Appendix 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight Latest Reports by DelveInsight Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get

7. hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us: Kritika Rehani Team Lead, Marketing krehani@delveinsight.com +91-9650213330